Capricor Therapeutics Inc., of Los Angeles, said the FDA has cleared its investigational new drug application to conduct a trial of CAP-1002, its lead investigational therapy, in boys and young men in advanced stages of Duchenne muscular dystrophy. The randomized, double-blind, placebo-controlled trial will be called Hope-2 and is designed to evaluate the safety and efficacy of intravenous, repeat doses of CAP-1002.